PRVB has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
PRVB has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Provention Bio's annualized Net Income for the quarter that ended in Dec. 2022 was $-133.11 Mil. Provention Bio's average Total Assets over the quarter that ended in Dec. 2022 was $215.38 Mil. Therefore, Provention Bio's annualized ROA % for the quarter that ended in Dec. 2022 was -61.80%.
The historical rank and industry rank for Provention Bio's ROA % or its related term are showing as below:
During the past 7 years, Provention Bio's highest ROA % was -58.68%. The lowest was -91.91%. And the median was -72.04%.
The historical data trend for Provention Bio's ROA % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Provention Bio Annual Data | ||||||||||||||||
Trend | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | |||||||||
ROA % | Get a 7-Day Free Trial | -63.08 | -58.68 | -91.91 | -86.64 | -60.98 |
Provention Bio Quarterly Data | ||||||||||||||||||||
Mar18 | Jun18 | Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | |
ROA % | Get a 7-Day Free Trial | -70.40 | -68.10 | -104.71 | -76.80 | -61.80 |
For the Biotechnology subindustry, Provention Bio's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Provention Bio's ROA % distribution charts can be found below:
* The bar in red indicates where Provention Bio's ROA % falls into.
Provention Bio's annualized ROA % for the fiscal year that ended in Dec. 2022 is calculated as:
ROA % | = | Net Income (A: Dec. 2022 ) | / | ( (Total Assets (A: Dec. 2021 ) | + | Total Assets (A: Dec. 2022 )) | / count ) |
= | -113.565 | / | ( (135.621 | + | 236.856) | / 2 ) | |
= | -113.565 | / | 186.2385 | ||||
= | -60.98 % |
Provention Bio's annualized ROA % for the quarter that ended in Dec. 2022 is calculated as:
ROA % | = | Net Income (Q: Dec. 2022 ) | / | ( (Total Assets (Q: Sep. 2022 ) | + | Total Assets (Q: Dec. 2022 )) | / count ) |
= | -133.108 | / | ( (193.913 | + | 236.856) | / 2 ) | |
= | -133.108 | / | 215.3845 | ||||
= | -61.80 % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Dec. 2022) net income data. ROA % is displayed in the 30-year financial page.
Provention Bio (NAS:PRVB) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
ROA % | (Q: Dec. 2022 ) | ||
= | Net Income | / | Total Assets |
= | -133.108 | / | 215.3845 |
= | (Net Income / Revenue) | * | (Revenue / Total Assets) |
= | (-133.108 / 43.252) | * | (43.252 / 215.3845) |
= | Net Margin % | * | Asset Turnover |
= | -307.75 % | * | 0.2008 |
= | -61.80 % |
Note: The Net Income data used here is four times the quarterly (Dec. 2022) net income data. The Revenue data used here is four times the quarterly (Dec. 2022) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
Thank you for viewing the detailed overview of Provention Bio's ROA % provided by GuruFocus.com. Please click on the following links to see related term pages.
Sessa Capital (master), L.p. | 10 percent owner | 888 SEVENTH AVENUE, 30TH FLOOR, NEW YORK NY 10019 |
Ashleigh Palmer | director, 10 percent owner, officer: President and CEO | PROVENTION BIO, INC., 110 OLD DRIFTWAY LANE, LEBANON NJ 08833 |
Francisco Leon | director, 10 percent owner, officer: Chief Scientific Officer | C/O PROVENTION BIO, INC., 110 OLD DRIFTWAY LANE, LEBANON NJ 08833 |
Jason Hoitt | officer: Chief Commercial Officer | C/O DOVA PHARMACEUTICALS, INC., 240 LEIGH FARM ROAD, SUITE 245, DURHAM NC 27707 |
Justin Vogel | officer: Chief Accounting Officer | C/O PROVENTION BIO, INC., 55 BROAD STREET, RED BANK NJ 07701 |
Rita Jain | director | C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, SUITE 1100, CAMBRIDGE MA 02142 |
Sarah O'brien | officer: Chief People Officer | C/O PROVENTION BIO, INC., 55 BROAD STREET, RED BANK NJ 07701 |
Sessa Capital Im, L.p. | 10 percent owner | 888 SEVENTH AVENUE, 30TH FLOOR, NEW YORK NY 10019 |
John Petry | 10 percent owner | 888 SEVENTH AVENUE, 30TH FLOOR, NEW YORK NY 10019 |
Sessa Capital Gp, Llc | 10 percent owner | 888 SEVENTH AVENUE, 30TH FLOOR, NEW YORK NY 10019 |
Sessa Capital Im Gp, Llc | 10 percent owner | 888 SEVENTH AVENUE, 30TH FLOOR, NEW YORK NY 10019 |
Miyoko Christina Yi | officer: Chief Operations Officer | C/O PROVENTION BIO, INC., 55 BROAD STREET, 2ND FLOOR, RED BANK NJ 07701 |
Benedict Osorio | officer: Chief Quality Officer | ONE WORLD TRADE CENTER, 47TH FLOOR, SUITE J, NEW YORK NY 10007 |
Eleanor Ramos | officer: Chief Medical Officer & COO | ZYMOGENETICS, INC., 1201 EASTLAKE AVENUE E, SEATTLE WA 98102 |
Thierry Chauche | officer: Chief Financial Officer | C/O PROVENTION BIO, INC., 55 BROAD STREET, 2ND FLOOR, RED BANK NJ 07701 |
From GuruFocus
By PRNewswire PRNewswire • 07-13-2022
By PRNewswire PRNewswire • 11-03-2022
By sperokesalga sperokesalga • 03-29-2023
By PRNewswire PRNewswire • 07-03-2022
By PRNewswire PRNewswire • 01-05-2023
By PRNewswire PRNewswire • 07-03-2022
By PRNewswire PRNewswire • 08-04-2022
By PRNewswire PRNewswire • 12-02-2022
By sperokesalga sperokesalga • 03-17-2023
By PRNewswire PRNewswire • 07-28-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.